SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after launching a $49 compounded GLP-1 weight-loss pill, sparking legal threats from Novo Nordisk and a swift FDA warning against non-approved compounded drugs. The community is sharply divided, debating whether this is a bold, disruptive move to make healthcare affordable or a risky, potentially illegal strategy that could lead to significant legal and financial repercussions for the company.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as it takes legal and regulatory action against Hims & Hers for launching a cheaper, compounded version of its Wegovy pill, igniting a fierce debate over intellectual property and product integrity in the expanding obesity drug market. The community is actively discussing whether these crackdowns will solidify Novo Nordisk's market leadership despite previous conservative guidance.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit (RDDT) is trending as its stock faces a significant sell-off despite reporting strong Q4 earnings, robust revenue growth, and a $1 billion share buyback. Many in the community are calling the sharp decline 'manipulation' and a 'gift' for long-term buyers, while analysts offer mixed revised price targets, contributing to a debate on its valuation and growth trajectory amidst an otherwise green market.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is seeing significant conversation as its strong Q4 earnings and robust GLP-1 pipeline are balanced against the FDA's delayed decision for its oral weight-loss drug and competitive pressure from cheaper compounded alternatives. The community is actively debating how regulatory actions against copycat drugs will shape Lilly's long-term pricing power and market leadership in the rapidly evolving obesity treatment landscape.

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

Pulse Biosciences Inc

Pulse Biosciences is trending due to its groundbreaking FDA Breakthrough Device Designation for its CellFX nsPFA Cardiac Surgery System and positive first-in-human study results across cardiac and soft tissue applications. The community is enthusiastically discussing the "game-changing" potential of its nanosecond PFA technology, anticipating substantial upside for this medical device innovator.

ETF Opportunities Trust - T-Rex 2X Inverse MSTR Daily Target ETF

T-Rex 2X Inverse MSTR Daily Target ETF

MSTZ, a 2x inverse ETF of MicroStrategy (MSTR), is trending as the community eyes MSTR's persistent weakness despite Bitcoin's recent rally, fueled by ongoing concerns about MSTR's share dilution and heavy institutional shorting. Investors are actively positioning for further downside in MSTR, viewing MSTZ as a direct play on its anticipated decline.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler is undergoing a significant sell-off following its earnings report, prompting community debate over whether the market is unfairly lumping the cybersecurity leader with other software companies perceived as vulnerable to AI disruption, despite many believing ZS is oversold and vital for an AI-integrated future.

BlackRock Institutional Trust Company N.A. - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF ($IGV) is experiencing a dramatic sell-off, with fears surrounding AI disruption from tools like Anthropic's Claude Cowork fueling a 'SaaSpocalypse' narrative. Despite this, the community is actively debating whether the decline is an overblown, short-seller-driven capitulation, anticipating that established software companies will ultimately integrate and benefit from AI innovation.

Braze, Inc. operates a customer relationship management platform for mobile applications. Its application combines messaging, audience segmentation, analytics and user support in a single integrated solution. The firm offers push notifications, email, in-app messages, and news feed services. The company was founded by Mark Ghermezian, William Magnuson, and Jonathan Hyman in 2011 and is headquartered in New York, NY.

Braze Inc - Ordinary Shares - Class A

Braze Inc

Braze is trending following a significant earnings beat and raised guidance for its customer engagement platform, with the community bullish on its performance and optimistic about continued analyst upgrades for its AI-driven solutions.

Forgent Power Solutions Inc. - Ordinary Shares - Class A

Forgent Power Solutions

Forgent Power Solutions (FPS) is trending following its recent IPO, with investors recognizing its position as a pureplay electrical distribution equipment provider amidst surging demand for AI data centers and grid modernization. The community is actively discussing its strong revenue and backlog growth, alongside its niche in custom power solutions for critical infrastructure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Polyrizon Partners With Clearmind To Advance Intranasal MEAI For CNS Disorders

(RTTNews) - Clearmind Medicine (CMND) announced that it has entered into a development agreement with Polyrizon to create a proprietary intranasal formulation of MEAI, a non-hallucinogenic...

Small Cap Stocks To Keep An Eye On - December 4th

SMX (Security Matters) Public, Spring Valley Acquisition, Direxion Daily META Bull 2X Shares, Polyrizon, and Direxion Daily TSLA Bear 1X Shares are the five Small Cap stocks to watch today, according...

Top Biotech Stocks To Consider - December 4th

Danaher, Polyrizon, Vertex Pharmaceuticals, Medpace, Abivax, Capricor Therapeutics, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

Polyrizon Stock Skyrockets After New Data Shows Naloxone Gel Outperforms Marketed Spray

Polyrizon stock is up on new data showing its naloxone hydrogel formulation has stronger and longer-lasting mucosal retention.read more...

What Sparked Polyrizon's (PLRZ) 140% After-Hours Stock Surge?

Polyrizon surged in nearly 140% after-hours trading following preclinical data showing its naloxone hydrogel outperforms a marketed spray and a key manufacturing milestone.read more...

Polyrizon Hits Key Breakthrough That Brings Its Nasal Spray Closer To 2026 Trials

Polyrizon jumps over 100%. The company completes major manufacturing milestone for its proprietary nasal-spray product platform.read more...

<ul class="summary-bullets"><li>The expanded production ensures that the PL-14 spray can be reliably manufactured at higher volumes.</li><li>Following the update, Polyrizon’s stock traded over 82% higher in Tuesday’s premarket.</li><li>The upscaled process is designed to provide clinical trial material (CTM) for studies scheduled to begin in 2026.</li></ul>Polyrizon (PLRZ) announced on Tuesday a major manufacturing milestone for its proprietary nasal spray platform, bringing the company closer to supporting upcoming clinical trials and potential commercial availability.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/PLRZ">Polyrizon’s stock</a> traded over 73% higher in Tuesday’s premarket. On Stocktwits, retail sentiment for the stock improved to ‘extremely bullish’ from ‘bullish’ territory, amid ‘high’ message volumes.&nbsp;<h2 class="st-heading-2">Milestone Achievement</h2>Polyrizon successfully scaled its production process from small laboratory batches to larger, controlled manufacturing runs, validating the key parameters of its PL-14 formulation.&nbsp;The expanded production ensures that the PL-14 spray can be reliably manufactured at higher volumes while maintaining the quality standards necessary for clinical trials.<blockquote>"The process validated our manufacturing strategy.”&nbsp;-Tomer Izraeli, CEO, Polyrizon&nbsp;</blockquote>“With this batch in hand, we are energized and prepared to advance into next batches towards clinical trial material manufacturing, which we believe brings us one step closer to addressing the unmet needs in the nasal spray market."<h2 class="st-heading-2">Preparing For Clinical Trials</h2>The upscaled process is designed to provide clinical trial material (CTM) for studies scheduled to begin in 2026. Polyrizon’s manufacturing procedures align with theU.S. and European regulatory requirements.The PL-14 nasal spray is engineered to create a fast-acting, moisturizing barrier in the nasal cavity, helping trap, isolate, and neutralize airborne allergens before they contact mucosal tissues. Developed using Polyrizon’s proprietary Capture &amp; Contain (C&amp;C) bio-adhesive technology, the spray offers extended, non-pharmacological protection for people exposed to high levels of environmental allergens.&nbsp;PLRZ stock has lost over 99% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mongodb-stock-rises-premarket-as-analysts-increase-price-targets/cLIajIsRE0t">MongoDB’s Atlas Engine Drives A Wave Of Price Target Hikes – Stock Pops In Premarket Trade</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did Polyrizon Stock Soar Pre-Market Today? 

Polyrizon successfully scaled its production process from small laboratory batches to larger, controlled manufacturing runs, validating the key parameters of its PL-14 formulation. 

Equity

Polyrizon successfully scaled its production process from small laboratory batches to larger, controlled manufacturing runs, validating the key parameters of its PL-14 formulation. 


Polyrizon Ltd (PLRZ)&nbsp;led the pack with a 23% increase in weekly followers after the development-stage biotech company dropped plans to undergo a 1-for-10 reverse stock split, which led to shares surging nearly fourfold on Friday.The Israel-based company specializes in preventing biological threats, including allergens and viruses, from penetrating mucosal tissues — an area that has gained new relevance in the post-COVID-19 world.Last month, Polyrizon reported promising preliminary safety results for its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/plrz-stock-surges-on-manufacturing-deal-for-trial/cJaVyHWR1U">PL-14</a> Allergy Blocker, a mucoadhesive nasal gel spray designed to create a physical barrier against airborne allergens. The company expects to launch clinical trials in the U.S. and Europe by late 2025 or early 2026.Polyrizon stock has lost over half its value this year.Pheton Holdings (PTHL)&nbsp;saw a 19% rise in retail follower growth over the past week despite the absence of any news catalyst.The Beijing, China-based healthcare solution provider specializes in treatment planning systems for brachytherapy and other related products and services.The company's shares debuted on the Nasdaq in September 2024 and have gained a little over 4% since. However, their performance has been less than stellar year to date, with a loss of over 5%.AirSculpt Technologies (AIRS)&nbsp;posted an 8% jump in weekly Stocktwits follower additions. The body contouring specialist reported better-than-expected quarterly results and forecast full-year revenue of about $160 million to $170 million, which topped Wall Street estimates.Shares of the Miami Beach, Florida-based company, which offers minimally invasive fat removal procedures, have lost over 42% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Polyrizon, Pheton, AirSculpt: Top 3 Healthcare Stocks With Soaring Weekly Retail Interest

A trio of small-cap healthcare stocks caught the attention of retail investors last week, posting sharp jumps in follower growth on Stocktwits. 

Shares of Polyrizon skyrocketed more than 200% to an all-time high on Wednesday, making it the top biotech stock with the most new followers on Stocktwits in the past 24 hours.&nbsp;Trading volume surged 890 times the daily average, reflecting heightened investor interest in the Israel-based biotech company.The massive rally follows Polyrizon’s announcement of a manufacturing agreement with Eurofins CDMO Amatsiaquitaine, a prominent European Good Manufacturing Practice (GMP) manufacturer.&nbsp;This collaboration will supply clinical trial material for Polyrizon’s experimental allergy blocker, PL-14, which is set to enter clinical trials in 2025.The PL-14 allergy blocker is part of Polyrizon’s effort to develop innovative nasal sprays that create a hydrogel-based shield in the nasal cavity, protecting against allergens and viruses.&nbsp;The manufacturing deal secures a compliant supply chain for the clinical trial, marking a key milestone for the development-stage biotech firm.Retail chatter on Stocktwits has been overwhelmingly bullish.<stembedurl>https://stocktwits.com/TraderUKBoyy/message/597012617</stembedurl><stembedurl>https://stocktwits.com/Dollarpee/message/597017164</stembedurl>Polyrizon’s stock had a rocky start on the Nasdaq, debuting at the end of October with a disappointing IPO.&nbsp;The company priced 958,903 units at $4.38 per unit, with each unit including one ordinary share and three warrants exercisable at the same price. Shares dropped more than 64% post IPO.Despite the poor debut, Polyrizon has gained 90% so far this year following Wednesday’s surge, although it remains below its IPO price.&nbsp;Over the past month, the stock has seen a meteoric rise in popularity, adding 1,576% more followers on Stocktwits amid a 10,300% spike in message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Polyrizon's Retail Following Booms As Biotech Stock Triples On Manufacturing Deal For Allergy Blocker Trial

This collaboration will supply clinical trial material for Polyrizon’s experimental allergy blocker, PL-14, which is set to enter clinical trials in 2025.

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Polyrizon Ltd.

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

PLRZ
Polyrizon Ltd. Ordinary Shares

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest PLRZ News

PLRZPolyrizon Ltd. Ordinary Shares